drugset / Trial / NCT07074327

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327

Phase 1 Completed 74 enrolled Vertex Pharmaceuticals Incorporated
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.

Timeline

Start
2025-07-11
Primary completion
2026-02-20
Completion
2026-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule Oral
Subject Norethindrone Unknown Oral
Subject Norgestimate Small molecule Oral
Subject VX-407 Unknown Oral
Subject drospirenone Unknown Oral
Subject ethinyl estradiol Small molecule Oral